Advertisement
SuperGen's presentations will review clinical and non-clinical advances inthe following compounds: SGI-1776, SGI-1252, and SGI-110. All presentationswill occur as poster presentations.
Advertisement
About SuperGen
Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical companydedicated to the discovery and development of novel cancer therapies. SuperGenis developing a number of therapeutic anticancer products focused on kinaseand cell signaling inhibitors and DNA methyltransferase inhibitors. For moreinformation about SuperGen, please visit http://www.supergen.com.Abstract Number/Title Date Abstract 1922: Inhibiting PIM-1 is Effective in Vitro and in Vivo against ALL: A Novel Mechanistic and Potentially Clinically Relevant Druggable Target Dec 7 Abstract 2629: Preclinical Characterization of the JAK-2 Inhibitor, SGI-1252 Dec 7 Abstract 3355: Anti-AML Activity of Combined Epigenetic Therapy with Novel DNMT1 Inhibitors SGI-110 or SGI-1036 and Histone Deacetylase Inhibitor Panobinostat Dec 8
SOURCE SuperGen, Inc.
